T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.81B |
| 2 |
Boeing
BA
|
+$1.68B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.33B |
| 4 |
Amphenol
APH
|
+$1.11B |
| 5 |
CME Group
CME
|
+$902M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$3.65B |
| 2 |
Advanced Micro Devices
AMD
|
+$2.51B |
| 3 |
UnitedHealth
UNH
|
+$2.06B |
| 4 |
Uber
UBER
|
+$1.84B |
| 5 |
Adobe
ADBE
|
+$1.44B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.21% |
| 2 | Healthcare | 12.77% |
| 3 | Consumer Discretionary | 11.71% |
| 4 | Financials | 11.15% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2176
Liberty Latin America Class C
LILAK
$1.67B
| $634K | ﹤0.01% |
109,883
-12,749
| -10% | -$92.6K |
|
|
WAY
2177
Waystar Holding Corp
WAY
$4.81B
| $634K | ﹤0.01% |
17,271
+3,070
| +22% | +$94.4K |
|
2178
Atomera
ATOM
$212M
| $632K | ﹤0.01% |
54,400
+8,700
| +19% | +$50.1K |
|
2179
MVB Financial
MVBF
$397M
| $632K | ﹤0.01% |
30,486
+4,255
| +16% | +$87.8K |
|
2180
Vishay Precision Group
VPG
$908M
| $632K | ﹤0.01% |
26,901
+2,581
| +11% | +$60.4K |
|
2181
Green Dot
GDOT
$766M
| $627K | ﹤0.01% |
58,896
+10,422
| +22% | +$115K |
|
2182
Trupanion
TRUP
$1.33B
| $626K | ﹤0.01% |
12,974
+2,202
| +20% | +$113K |
|
2183
Buckle
BKE
$2.33B
| $623K | ﹤0.01% |
12,253
+2,127
| +21% | +$101K |
|
2184
Shoals Technologies Group
SHLS
$1.37B
| $623K | ﹤0.01% |
112,523
-29,400
| -21% | -$149K |
|
2185
Ingles Markets
IMKTA
$1.66B
| $620K | ﹤0.01% |
9,611
+936
| +11% | +$63K |
|
2186
Genesco
GCO
$391M
| $616K | ﹤0.01% |
14,392
+650
| +5% | +$21.4K |
|
2187
Burke & Herbert Financial Services Corp
BHRB
$1.48B
| $613K | ﹤0.01% |
9,829
+5,319
| +118% | +$348K |
|
2188
Scansource
SCSC
$1.06B
| $612K | ﹤0.01% |
12,897
+1,358
| +12% | +$66.4K |
|
2189
Compass Diversified
CODI
$924M
| $611K | ﹤0.01% |
26,445
+4,632
| +21% | +$104K |
|
2190
Theravance Biopharma
TBPH
$878M
| $610K | ﹤0.01% |
64,795
+9,315
| +17% | +$84.8K |
|
2191
BrightView Holdings
BV
$1.08B
| $608K | ﹤0.01% |
37,990
+3,779
| +11% | +$62.9K |
|
2192
Appian
APPN
$2.65B
| $605K | ﹤0.01% |
18,329
-76,203
| -81% | -$2.72M |
|
2193
Castle Biosciences
CSTL
$960M
| $605K | ﹤0.01% |
22,697
+1,837
| +9% | +$55.9K |
|
2194
Myriad Genetics
MYGN
$303M
| $605K | ﹤0.01% |
44,089
-10,253
| -19% | -$189K |
|
|
JAMF
2195
DELISTED
Jamf
JAMF
| $604K | ﹤0.01% |
42,935
+5,109
| +14% | +$80.6K |
|
2196
CALL
Albertsons Companies
ACI
$6.02B
| $602K | ﹤0.01% |
+30,700
| New | +$582K |
|
2197
Greenlight Captial
GLRE
$505M
| $600K | ﹤0.01% |
42,827
+7,321
| +21% | +$104K |
|
2198
NVE Corp
NVEC
$563M
| $600K | ﹤0.01% |
7,363
+939
| +15% | +$73.6K |
|
2199
Nuvation Bio
NUVB
$2.14B
| $599K | ﹤0.01% |
225,025
+9,758
| +5% | +$25.1K |
|
2200
Shore Bancshares
SHBI
$801M
| $599K | ﹤0.01% |
37,746
-12,213
| -24% | -$189K |
|
Similar funds
T. Rowe Price Associates's Q4 2024 Portfolio in Review
As of Q4 2024, T. Rowe Price Associates held 3,110 positions worth $867B, down 0.13% from $869B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
T. Rowe Price Associates's Q4 2024 filing shows 92 new, 1,805 increased, 946 reduced and 96 closed positions. Its largest new stake was South Bow Corp: 12,337,055 shares worth $291M. The largest sale was Apple, an estimated $3.65B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2024 buy was South Bow Corp: 12,337,055 shares worth $291M.
- T. Rowe Price Associates added most to Broadcom in Q4 2024, an estimated $2.81B increase.
- T. Rowe Price Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $3.65B.
- T. Rowe Price Associates fully exited Tempus AI in Q4 2024, selling an estimated $292M.
- T. Rowe Price Associates's ten largest holdings make up 35% of its $867B portfolio in Q4 2024.
- T. Rowe Price Associates opened 92 new positions and closed 96 in Q4 2024.
- T. Rowe Price Associates's portfolio value fell 0.13% quarter-over-quarter to $867B.
Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.